Extract

PDQ (Physician Data Query) is the National Cancer Institute’s source of comprehensive cancer information. It contains peer-reviewed, evidence-based cancer information summaries on treatment, supportive care, screening, prevention, genetics, and complementary and alternative medicine. The summaries are regularly updated by six editorial boards. The following PDQ summaries were recently updated:

Gadner H, Minkov M, Grois N, et al: Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood 121(25): 5006–14, 2013. PMID: 23589673

The PDQ Langerhans Cell Histiocytosis (LCH) Treatment summary has been revised to include results of the LCH-III study. The LCH-III study evaluated patients without risk organ involvement who were randomly assigned to either 6 months or 12 months of vinblastine plus prednisone chemotherapy. Patients who received 12 months of therapy had a lower 5-year reactivation rate (37%) than patients who received 6 months of therapy (54%; P = .03) and patients treated with historical 6-month schedules (52% [LCH-I] and 48% [LCH-II]; P < .001). To review the summary, please use the following link: http://www.cancer.gov/cancertopics/pdq/treatment/lchistio/HealthProfessional/page7

You do not currently have access to this article.